Two-year data from a phase 3 trial of exenatide in Parkinson’s is due later this year and could help answer that question, said Prof Foltynie.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback